Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Identification of circulating apolipoprotein M as a new determinant of insulin sensitivity and relationship with adiponectin

Frances L., Croyal M., Ruidavets JB., Maraninchi M., Combes G., Raffin J.

Prospective Study with a reported sample of 169 on Type 2 Diabetes, published in Int J Obes (Lond) (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Int J Obes (Lond) (2024)
Reported sample size
169
Source database
Europe PMC
PMID
38491190
PMCID
PMC11216985
DOI
10.1038/s41366-024-01510-w
NCT
NCT01277068
Citations
6

Abstract (original English)

Background The adiponectin is one of the rare adipokines down-regulated with obesity and protects against obesity-related disorders. Similarly, the apolipoprotein M (apoM) is expressed in adipocytes and its expression in adipose tissue is associated with metabolic health. We compared circulating apoM with adiponectin regarding their relationship with metabolic parameters and insulin sensitivity and examined their gene expression patterns in adipocytes and in the adipose tissue. Methods Circulating apoM and adiponectin were examined in 169 men with overweight in a cross-sectional study, and 13 patients with obesity during a surgery-induced slimming program. Correlations with clinical parameters including the insulin resistance index (HOMA-IR) were analyzed. Multiple regression analyses were performed on HOMA-IR. The APOM and ADIPOQ gene expression were measured in the adipose tissue from 267 individuals with obesity and a human adipocyte cell line. Results Participants with type 2 diabetes had lower circulating adiponectin and apoM, while apoM was higher in individuals with dyslipidemia. Similar to adiponectin, apoM showed negative associations with HOMA-IR and hs-CRP (r 0.3). Unlike adiponectin, apoM was positively associated with LDL markers (LDL-C and apoB100, r 0.44) as well as in adipocytes (r > 0.81). In adipocytes, APOM was downregulated by inflammatory factors and upregu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAdipocytesHumansDiabetes Mellitus, Type 2Insulin ResistanceObesityApolipoproteinsCross-Sectional StudiesAdultMiddle Aged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research